Dr. Hurvitz on the Expanding Metastatic HER2+ Breast Cancer Treatment Arsenal

Publication
Video
Supplements And Featured PublicationsYear in Review: HER2+ Updates in Oncology
Volume 1
Issue 1

In Partnership With:

Sara A. Hurvitz, MD, discusses the expanding HER2-positive metastatic breast cancer treatment arsenal.

Sara A. Hurvitz, MD, director of the Breast Cancer Clinical Research Program and co-director of the Santa Monica University of California Los Angeles (UCLA) Outpatient Hematology/Oncology Practice, as well as an assistant professor of medicine in the Division of Hematology/Oncology of the David Geffen School of Medicine at UCLA, discusses the expanding HER2-positive metastatic breast cancer treatment arsenal.

Over the past year or so, several agents have emerged in the paradigm, according to Hurvitz. In December 2019, the FDA approved single-agent fam-trastuzumab deruxtecan-nxki (Enhertu) for use in patients who had received 2 or more prior HER2-based therapies in the metastatic setting. The regulatory decision was based on data from the phase 2 DESTINY-Breast01 trial. Then in February 2020, the FDA gave the green light to neratinib (Perjeta) plus capecitabine for use in the third-line setting and beyond.

A couple of months later, in April 2020, the FDA approved tucatinib (Tukysa) plus capecitabine and trastuzumab (Herceptin) for use in the second-line setting and beyond, including patients with brain metastases. Most recently, in December 2020, margetuximab-cmkb (Margenza) plus chemotherapy received regulatory approval for those who had previously received 2 or more HER2-targeted regimens, at least 1 of which for metastatic disease, concludes Hurvitz.

Related Videos
Reshma Jagsi, MD, DPhil, Emory University
Jane L. Meisel, MD, Emory University
Pooja Advani, MBBS, MD, Mayo Clinic
Nicholas P. McAndrew, MD, MSCE, University of California, Los Angeles Health
Pooja Advani, MBBS, MD